Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
Open Access
- 27 December 2019
- Vol. 9 (1), 77
- https://doi.org/10.3390/cells9010077
Abstract
CD38 is a type II glycoprotein highly expressed on plasmablasts, short-lived and long-lived plasma cells, but weakly expressed on other lymphoid cells, myeloid cells and non-hematopoietic cells. This expression pattern makes CD38 an interesting target for a targeted therapy aiming to deplete antibody-producing plasma cells. We present data suggesting that anti-CD38 therapy may be effective for the prevention at the preclinical stage and for the treatment of established autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Given the high unmet need for efficacious disease-modifying treatment in these diseases, studies are warranted to determine if anti-CD38 antibody-based therapies may delay or prevent the disease progression of systemic autoimmune diseases.This publication has 72 references indexed in Scilit:
- B-cell populations and sub-populations in Sjögren's syndromeLa Presse Médicale, 2012
- Molecular Characterization of Circulating Plasma Cells in Patients with Active Systemic Lupus ErythematosusPLOS ONE, 2012
- Myeloperoxidase-Specific Plasma Cell Depletion by Bortezomib Protects from Anti-Neutrophil Cytoplasmic Autoantibodies–Induced GlomerulonephritisJournal of the American Society of Nephrology, 2011
- Long-lived autoreactive plasma cells drive persistent autoimmune inflammationNature Reviews Rheumatology, 2011
- Salivary glands of primary Sjogren's syndrome patients express factors vital for plasma cell survivalArthritis Research & Therapy, 2011
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisThe New England Journal of Medicine, 2010
- Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritisProceedings of the National Academy of Sciences of the United States of America, 2010
- CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus PatientsImmunity, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- Differential B- and T-cell activation in Wegener’s granulomatosisJournal of Allergy and Clinical Immunology, 1999